KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
1.050
+0.125 (13.51%)
At close: Dec 4, 2025, 4:00 PM EST
1.020
+0.056 (5.81%)
Pre-market: Dec 5, 2025, 6:08 AM EST
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
8.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
| Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
| Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KALA News
- 19 hours ago - KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday? - Benzinga
- 4 months ago - Kala Bio (KALA) Q2 Loss Widens 15% - The Motley Fool
- 4 months ago - KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 5 months ago - KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - GlobeNewsWire
- 6 months ago - KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 10 months ago - KALA BIO Announces Chief Executive Officer Transition - GlobeNewsWire